A new study will investigate whether SGLT-2 inhibitor Farxiga can delay the progression of heart failure in people with and without type 2 diabetes Continue Reading »

Contribute data to a new study on how overnight blood sugars affect sleep, activity, and mental state; four-week “virtual” trial recruiting people with type 1 on Dexcom CGM and a compatible pump Continue Reading »

A study recruiting 10,000 people will look at whether Zynquista (sotagliflozin) has effects beyond glucose-lowering and weight loss Continue Reading »

Recruiting now! This major study will support FDA submission of Tandem’s t:slim X2 with Control-IQ and Dexcom G6 in people with type 1 ages 14 and up; includes automatic boluses for high blood sugars Continue Reading »

A new study is investigating whether higher doses of injectable GLP-1 agonist Trulicity (dulaglutide) are more effective; it is recruiting 1,800 participants with type 2 diabetes Continue Reading »

Two new studies will investigate whether SGLT-2 inhibitor Jardiance impacts heart failure in people with and without diabetes. Jardiance is already approved to lower A1C and reduce the risk of heart-related death Continue Reading »

Learn more about the All of Us Research Program, a massive national effort to collect individual health data to support precision medicine research Continue Reading »

Two new studies will investigate whether SGLT-2 inhibitor Farxiga impacts heart failure in people with type 2 diabetes and prediabetes Continue Reading »